Key Points
- Opaleye Management Inc. bought 2,524 shares of SLGL on Dec. 3 at $37.81 for $95,432.44, bringing its stake to 370,964 shares (valued around $14.03M) — the firm also purchased 4,340 shares on Dec. 1 at $37.37 for $162,185.80.
- Sol‑Gel reported a quarterly loss of ($2.13) EPS, missed estimates, and posts negative margins and ROE; analysts hold a consensus Hold rating with an average target price of $50.00.
Sol-Gel Technologies Ltd. (NASDAQ:SLGL - Get Free Report) major shareholder Opaleye Management Inc. bought 2,524 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were purchased at an average price of $37.81 per share, for a total transaction of $95,432.44. Following the completion of the acquisition, the insider owned 370,964 shares of the company's stock, valued at $14,026,148.84. The trade was a 0.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Opaleye Management Inc. also recently made the following trade(s):
- On Monday, December 1st, Opaleye Management Inc. purchased 4,340 shares of Sol-Gel Technologies stock. The shares were purchased at an average cost of $37.37 per share, for a total transaction of $162,185.80.
Sol-Gel Technologies Price Performance
Shares of SLGL opened at $39.78 on Thursday. The company has a market cap of $110.83 million, a PE ratio of -12.20 and a beta of 1.36. The firm has a 50-day moving average of $36.61 and a 200-day moving average of $21.70. Sol-Gel Technologies Ltd. has a one year low of $4.02 and a one year high of $52.26.
Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last issued its earnings results on Thursday, November 20th. The company reported ($2.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($0.04). Sol-Gel Technologies had a negative net margin of 47.37% and a negative return on equity of 33.61%. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.30 million. Analysts expect that Sol-Gel Technologies Ltd. will post -0.28 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on SLGL. Weiss Ratings restated a "hold (c)" rating on shares of Sol-Gel Technologies in a research note on Friday, November 28th. HC Wainwright raised their price objective on shares of Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, October 27th. Zacks Research raised Sol-Gel Technologies to a "hold" rating in a research report on Tuesday, October 28th. Finally, Wall Street Zen lowered Sol-Gel Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $50.00.
Get Our Latest Stock Analysis on SLGL
About Sol-Gel Technologies
(
Get Free Report)
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
